Participant characteristics
Mullerian agenesis, congenital anomaly
UTERUS

were at least 18 years of age and age of majority according to local laws and regulationsmale participants:Male participants with partners of childbearing potential should have been willing to use reliable contraceptive methods throughout the study and for five half-lives of study drug plus 90 days, corresponding to 4 months after the last injection.female participants:Female participants not of childbearing potential may have participated and included those who were:infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation) or congenital anomaly (such as Mullerian agenesis) orpostmenopausal—defined as either:a woman at least 40 years of age with an intact uterus, not on hormone therapy and who had cessation of menses for at least 1 year without an alternative medical cause, and follicle-stimulating hormone ≥40 mIU mlora woman 55 years or older not on hormone therapy and who had at least 12 months of spontaneous amenorrheaora woman at least 55 years of age with a diagnosis of menopause before starting hormone replacement therapyFemale participants of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopausal) must have:tested negative for pregnancy at visit 1 based on a serum pregnancy testif sexually active, agreed to use two forms of effective contraception where at least one form was highly effective for the duration of the trial plus 30 days, corresponding to 2 months after the last injection; andnot have been breastfeedingNote: contraceptive use by men or women should have been consistent with local regulations regarding the methods of contraception for those participating in clinical studies.